Adial Pharmaceuticals, Inc.

NasdaqCM:ADIL Stok Raporu

Piyasa değeri: US$6.5m

Adial Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Adial Pharmaceuticals has a total shareholder equity of $4.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $4.9M and $671.9K respectively.

Anahtar bilgiler

0%

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranın/a
NakitUS$3.29m
EşitlikUS$4.28m
Toplam yükümlülüklerUS$671.88k
Toplam varlıklarUS$4.95m

Son finansal sağlık güncellemeleri

Recent updates

Adial Clinical Trial: A Fluff Or A Win?

Aug 22

Adial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01

Aug 16

Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst

Jun 21

Adial Pharmaceuticals shares +5% on receiving third patent for opioid use disorder candidate

Jan 11

Adial Pharmaceuticals inks stock purchase agreement with Keystone Capital

Nov 25

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ADIL's short term assets ($3.8M) exceed its short term liabilities ($671.9K).

Uzun Vadeli Yükümlülükler: ADIL has no long term liabilities.


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ADIL is debt free.

Borcun Azaltılması: ADIL had no debt 5 years ago.


Bilanço


Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ADIL has less than a year of cash runway based on its current free cash flow.

Tahmini Nakit Akışı: ADIL has less than a year of cash runway if free cash flow continues to reduce at historical rates of 15% each year


Sağlıklı şirketleri keşfedin